About Alentis Therapeutics
Alentis Therapeutics is a Healthcare company based in Basel (Switzerland) founded in 2019 by Thomas Baumert. Therapies for fibrosis, cirrhosis, and liver cancer are developed. Alentis Therapeutics has raised $365.66 million across 4 funding rounds from investors including Schroders, Orbimed and Bpifrance. Alentis Therapeutics was last valued at $2 billion in June 2021. Its chief executive, as recorded, is Roberto Iacone. Alentis Therapeutics offers products and services including ADC ALE.P02 and Lixudebart. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its legal entity is Alentis Therapeutics AG.
Company details
Alentis Therapeutics was founded in 2019 in Basel, Switzerland. Focus is placed on developing treatments for fibrosis, cirrhosis, and liver cancer within the biotechnology sector. A gene expression platform supports the advancement of monoclonal antibodies targeting the CLDN1 protein. These are investigated for advanced liver fibrosis, kidney fibrosis, hepatocellular carcinoma, and cholangiocarcinoma. Drug candidates in the pipeline include ALE-F02 and ALE-C04.
- Headquarters Basel, Switzerland
- Founders Thomas Baumert
- SectorsHealthcare
- Website alentis.ch
- Social LinkedIn YouTube
- Legal Name Alentis Therapeutics Ag
- Total Equity Funding$365.66M (USD)
in 4 rounds
- Latest Funding Round$181.4M (USD), Series D
Nov 2024
- InvestorsSchroders
& 13 more
Products & Services of Alentis Therapeutics
Alentis Therapeutics offers a comprehensive portfolio of products and services, including ADC ALE.P02 and Lixudebart.
Antibody-drug conjugate targeting squamous cancers for selective tumor cell killing.
Monoclonal antibody designed to reverse organ fibrosis through Claudin-1 targeting.
Apps and channels of Alentis Therapeutics
its YouTube channel Alentis Therapeutics has 14 subscribers and 7 videos.
Videos from Alentis Therapeutics
The most watched videos on Alentis Therapeutics's YouTube channel, Alentis Therapeutics (14 subscribers). Click a video to play it here.
More on Alentis Therapeutics.
Funding Insights of Alentis Therapeutics
Alentis Therapeutics has successfully raised a total of $365.66M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $181.4 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $365.66M
- Total Rounds 4
- Last Round Series D — $181.4M
- First Round $12.26M
(Apr 2019)
- Investors Count 14
All 4 funding rounds of Alentis Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $181.4M | Series D | – | Orbimed, Novo Holdings | |
| Apr 2023 | $105M | Series C | – | Jeito, Novo Holdings | |
| Jun 2021 | $67M | Series B | $2B | Morningside | |
| Apr 2019 | $12.26M | Series A | – | BioMedPartners, Pureos Bioventures |
| Date | Valuation | Stage |
|---|---|---|
| Jun 2021 | $2B | •••••••• |
Last known valuation $2B (Jun 2021). 14 investors in total: 14 institutional.
Investors in Alentis Therapeutics
Alentis Therapeutics has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Schroders, Orbimed and Bpifrance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Jeito Capital is focused on financing medical innovation globally. | jeito.life | Paris, France | ||
Healthcare investment firm focused on novel therapeutics development. | frazierls.com | Palo Alto, United States | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
Venture capital is provided to biomedical technology startups. | cataliocapital.com | New York, United States | ||
Multiple sectors are invested in by Morningside, a VC fund. | morningside.com | Newton, United States | ||
Venture capital is invested in innovative drug development companies. | pureosbio.com | Pfäffikon, Switzerland | ||
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
Early-stage investments are made in high-tech startups by HTGF. | htgf.de | Bonn, Germany |
Investor details for Alentis Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alentis Therapeutics
25 people are tracked at Alentis Therapeutics (17 in leadership, 5 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Thomas Baumert | Founder & Board Member | Leadership |
Roberto Iacone | CEO | Leadership |
Stella Augustus | Head Of Regulatory Affairs | Leadership |
Luigi Manenti | Chief Medical Officer | Leadership |
Sariette Witte | Head Of Communications | Leadership |
Markus Meyer | COO | Leadership |
Valentina Aureggi | VP BD & Strategic Partnerships | Leadership |
Nathalie Graf | Executive Assistant to the CEO | Leadership |
Alberto Toso | SVP & Head Oncology | Leadership |
Roberta Marchione | VP Head Of CMC | Leadership |
Marc Adamy | Vice President Program Management | Leadership |
Corentin Herbert | Director, Translational Research | Leadership |
Vincent Anquetil | Director Translational Data Science | Leadership |
Silke Appel-Dingemanse | Senior Director Business Development | Leadership |
Christos Hatzis | Vp, Head Of Translational Medicine | Leadership |
Jonathan Freve | Chief Financial Officer | Leadership |
Rizwan Velji | Chief Business Officer | Leadership |
Jason R Dinges | Director | Board & advisors |
Luca Santarelli | Chair | Board & advisors |
Rafaèle Tordjman | Director | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for Alentis Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alentis Therapeutics
4 dated milestones of Alentis Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Alentis Therapeutics is founded.
- Funding First funding round of $12.3M.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series D, of $181.4M.
Web traffic of Alentis Therapeutics
The website of Alentis Therapeutics (alentis.ch) receives about 3.9K visits a month.
- Monthly visits3.9K
▼ 6.1% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alentis Therapeutics
Complete news archive for Alentis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alentis Therapeutics
Alentis Therapeutics was founded in 2019.
Alentis Therapeutics is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Roberto Iacone is the CEO of Alentis Therapeutics, as recorded in our data.
Alentis Therapeutics is a funded company, having raised a total of $365.66M across 4 funding rounds to date. The company's 1st funding round was a Series A of $12.26M, raised on Apr 2019.
Alentis Therapeutics was founded in 2019 in Basel, Switzerland. Focus is placed on developing treatments for fibrosis, cirrhosis, and liver cancer within the biotechnology sector. A gene expression platform supports the advancement of monoclonal antibodies targeting the CLDN1 protein. These are investigated for advanced liver fibrosis, kidney fibrosis, hepatocellular carcinoma, and cholangiocarcinoma. Drug candidates in the pipeline include ALE-F02 and ALE-C04.
Alentis Therapeutics offers ADC ALE.P02 and Lixudebart.
Alentis Therapeutics has 14 investors. Key investors include Schroders, Orbimed, Bpifrance, RA Capital, and Novo Holdings.
The valuation of Alentis Therapeutics is $2B as of Jun 2021.
Alentis Therapeutics operates through Alentis Therapeutics Ag.